Stock Analysis on Net
AI Tokens
Stock Analysis on Net

IQVIA Holdings Inc. (NYSE:IQV)

This company has been moved to the archive! The financial data has not been updated since November 1, 2023.

Current Ratio
since 2013

Microsoft Excel

Calculation

IQVIA Holdings Inc., current ratio, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).

1 US$ in millions

The analysis of the liquidity position from 2013 to 2022 reveals a progressive deterioration in the current ratio, shifting from a position of surplus liquidity to a deficit in the final two years of the period.

Current Ratio Trajectory
The current ratio experienced an initial upward trend, peaking at 1.51 in 2015. Following this peak, a consistent decline was observed, with the ratio falling to 1.05 by 2019. Despite a marginal recovery to 1.12 in 2020, the ratio dropped below the critical 1.0 threshold in 2021 (0.91) and further declined to 0.89 by the end of 2022.
Asset and Liability Growth Dynamics
Current assets grew steadily from US$ 1,946 million in 2013 to US$ 4,981 million in 2022. However, this expansion was outpaced by the growth of current liabilities, which increased from US$ 1,482 million in 2013 to US$ 5,578 million in 2022. A significant inflection point occurred in 2016, where current liabilities rose sharply from US$ 1,594 million to US$ 2,705 million, initiating the long-term downward pressure on the liquidity ratio.
Liquidity Implications
Between 2013 and 2020, current assets consistently exceeded current liabilities, indicating an adequate capacity to meet short-term obligations. The transition to a current ratio below 1.0 in 2021 and 2022 indicates a shift in the short-term financial structure, where immediate liabilities now outweigh available current assets. This suggests a heightened reliance on operational cash flow or external financing to manage short-term debts.

AI Ask an analyst for more

My previous chats

Add tokens

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?

Comparison to Competitors

IQVIA Holdings Inc., current ratio, long-term trends, comparison to competitors

Microsoft Excel
IQVIA Holdings Inc. AbbVie Inc. Amgen Inc. Bristol-Myers Squibb Co. Danaher Corp. Eli Lilly & Co. Gilead Sciences Inc. Johnson & Johnson Merck & Co. Inc. Pfizer Inc. Regeneron Pharmaceuticals Inc. Thermo Fisher Scientific Inc. Vertex Pharmaceuticals Inc.
Dec 31, 2022 0.89 0.96 1.41 1.25 1.89 1.05 1.29 0.99 1.47 1.22 5.06 1.48 4.83
Dec 31, 2021 0.91 0.79 1.59 1.52 1.43 1.23 1.27 1.35 1.27 1.40 3.56 1.50 4.46
Dec 31, 2020 1.12 0.84 1.81 1.58 1.86 1.40 1.40 1.21 1.02 1.35 3.63 2.13 4.33
Dec 31, 2019 1.05 3.18 1.44 1.60 5.19 1.16 3.10 1.26 1.24 0.88 3.67 1.92 3.61
Dec 31, 2018 1.10 0.98 2.79 1.61 1.47 1.73 3.38 1.47 1.17 1.57 4.47 1.73 3.43
Dec 31, 2017 1.19 1.28 5.49 1.55 1.43 1.32 2.74 1.41 1.33 1.35 3.82 1.34 3.28
Dec 31, 2016 1.23 1.65 4.11 1.55 0.97 1.37 2.22 2.47 1.78 1.25 2.56 1.44 2.31
Dec 31, 2015 1.51 1.50 4.44 1.30 1.27 1.53 2.50 2.17 1.55 1.49 3.59 1.38 2.78
Dec 31, 2014 1.46 1.41 4.95 1.73 1.75 1.09 3.07 2.36 1.77 2.67 3.31 1.22 4.20
Dec 31, 2013 1.31 2.59 3.44 1.52 2.01 1.47 1.15 2.20 2.00 2.41 6.01 3.16 3.99

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).

Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

IQVIA Holdings Inc., current ratio, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel
IQVIA Holdings Inc. Pharmaceuticals, Biotechnology & Life Sciences
Dec 31, 2022 0.89 1.30
Dec 31, 2021 0.91 1.36
Dec 31, 2020 1.12 1.37
Dec 31, 2019 1.05 1.66
Dec 31, 2018 1.10 1.71
Dec 31, 2017 1.19 1.74
Dec 31, 2016 1.23 1.91
Dec 31, 2015 1.51 1.90
Dec 31, 2014 1.46 2.19
Dec 31, 2013 1.31 2.17

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).

Comparison to Industry (Health Care)

IQVIA Holdings Inc., current ratio, long-term trends, comparison to industry (health care)

Microsoft Excel
IQVIA Holdings Inc. Health Care
Dec 31, 2022 0.89 1.23
Dec 31, 2021 0.91 1.31
Dec 31, 2020 1.12 1.30
Dec 31, 2019 1.05 1.48
Dec 31, 2018 1.10 1.52
Dec 31, 2017 1.19 1.55
Dec 31, 2016 1.23 1.73
Dec 31, 2015 1.51 1.70
Dec 31, 2014 1.46 1.92
Dec 31, 2013 1.31 1.96

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31).